SCHEMBL26601686

SCHEMBL26601686

CCOC(=O)c1c(OCc2ccccc2)cc(Cl)nc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.50
KMT2A Q03164 3/20 0.50
KDM4E B2RXH2 3/20 0.50
LMNA P02545 3/20 0.50
NPC1 O15118 2/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSP90AA1 P07900 1/20 0.50
ADORA3 P0DMS8 5/20 0.49
MAPK1 P28482 1/20 0.46
PKM P14618 1/20 0.46
TP53 P04637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MCL1 Q07820 1/20 0.45
AGTR1 P30556 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31336208 1.00 RAB9A (0.50) RAB9AKMT2AKDM4ELMNANPC1
SCHEMBL5372093 0.88 AGTR1 (0.55) RAB9AKMT2AKDM4ELMNANPC1
SCHEMBL31518041 0.87 MCL1 (0.51) RAB9AKMT2ANPC1SMN1; SMN2MEN1
SCHEMBL26601663 0.87 MCL1 (0.51) RAB9AKMT2ANPC1SMN1; SMN2MEN1
SCHEMBL25151518 0.87 GAA (0.53) RAB9AKMT2AKDM4ENPC1GAA
SCHEMBL30593191 0.87 GAA (0.53) RAB9AKMT2AKDM4ENPC1GAA
SCHEMBL31517882 0.86 CA9 (0.49) LMNAMAPTSMN1; SMN2MCL1
SCHEMBL26601691 0.86 MCL1 (0.47) LMNAMAPTSMN1; SMN2MAPK1MCL1
SCHEMBL26608461 0.85 PTGER1 (0.47) KDM4ELMNAMAPTSMN1; SMN2MCL1
SCHEMBL26608317 0.84 MCL1 (0.46) RAB9ALMNANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
EP-4511115-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
EP-4511117-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A RAB9A 1794/4885KMT2A 3307/4885KDM4E 4442/4885
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN1B, CLIC1, HCN1 RAB9A 1871/4885KMT2A 3653/4885KDM4E 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.